SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN THE STATEMENTS FILED
PURSUANT TO RULES 13d-1(b), (c), and (d) AND AMENDMENTS THERETO
FILED PURSUANT TO RULE 13d-2(b)
(Amendment No. __)*
Transgenomic, Inc.
------------------
(Name of Issuer)
Common Stock, par value $0.01 per share
---------------------------------------
(Title of Class of Securities)
89365K206
--------------
(CUSIP Number)
October 31, 2005
-------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
SCHEDULE 13G
CUSIP NO. 89365K206 Page 2 of 6
-----------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)
Michael A. Roth and Brian J. Stark, as joint filers pursuant to
Rule 13d-1(k)
-----------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [X]
(b) [ ]
-----------------------------------------------------------------------------
3 SEC USE ONLY
-----------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States of America
-----------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES 0
--------------------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY 2,722,772 shares of Common Stock (See Item 4)
--------------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING 0
--------------------------------------------------------------
PERSON 8 SHARED DISPOSITIVE POWER
WITH 2,722,772 shares of Common Stock (See Item 4)
-----------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,722,772 shares of Common Stock (See Item 4)
-----------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
[X]
-----------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.5% (see Item 4)
-----------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON
IN
-----------------------------------------------------------------------------
SCHEDULE 13G
CUSIP NO. 89365K206 Page 3 of 6
Item 1(a). Name of Issuer:
Transgenomic, Inc. (the "Issuer")
Item 1(b). Address of Issuer's Principal Executive Offices:
12325 Emmet Street
Omaha, Nebraska 68164
Items 2(a),
(b) and (c). Name of Persons Filing, Address of Principal Business Office and
Citizenship:
This Schedule 13G is being filed on behalf of Michael A. Roth and
Brian J. Stark, as joint filers (collectively, the "Reporting
Persons").
The Reporting Persons have entered into a Joint Filing Agreement,
a copy of which is filed with this Schedule 13G as Exhibit 1,
pursuant to which the Reporting Persons have agreed to file this
Schedule 13G jointly in accordance with the provisions of Rule
13d-1(k) of the Securities Exchange Act of 1934, as amended.
The principal business office of the Reporting Persons is 3600
South Lake Drive, St. Francis, WI 53235. The Reporting Persons
are citizens of the United States of America.
Item 2(d). Title of Class of Securities:
Common Stock, par value $0.01 per share (the "Common Stock")
Item 2(e). CUSIP Number:
89365K206
Item 3. Not applicable
Item 4. Ownership.
(a) Amount beneficially owned:
2,722,772 shares of Common Stock*
(b) Percent of class:
Based on 49,172,079 shares of Common Stock of the Issuer
outstanding as of October 31, 2005, the Reporting Persons
hold approximately 5.5%* of the issued and outstanding
Common Stock of the Issuer.
SCHEDULE 13G
CUSIP NO. 89365K206 Page 4 of 6
(c) Number of shares to which such person has:
(i) Sole power to vote or direct the vote: 0
(ii) Shared power to vote or direct the vote: 2,722,772
shares of Common Stock*
(iii) Sole power to dispose or to direct the disposition
of: 0
(iv) Shared power to dispose of or direct the disposition
of: 2,722,772 shares of Common Stock*
*The Reporting Persons beneficially own an aggregate of
2,722,772 shares of Common Stock. The foregoing amount of
Common Stock and percentage ownership represent the combined
indirect holdings of Michael A. Roth and Brian J. Stark. The
Common Stock reported in this Schedule 13G does not include
1,089,109 shares of Common Stock issuable upon the exercise
of warrants held by the Reporting Persons. Such warrants
held by the Reporting Persons are subject to conversion caps
that preclude the holder thereof from utilizing its exercise
rights to the extent that it would beneficially own
(determined in accordance with Section 13(d) of the Exchange
Act) in excess of 4.99% and 9.99% of the Common Stock,
giving effect to such exercise.
All of the foregoing represents an aggregate of 2,722,772
shares of Common Stock held directly by SF Capital Partners
Ltd. ("SF Capital"). The Reporting Persons are the Managing
Members of Stark Offshore Management, LLC ("Stark
Offshore"), which acts as investment manager and has sole
power to direct the management of SF Capital. Through Stark
Offshore, the Reporting Persons possess voting and
dispositive power over all of the foregoing shares.
Therefore, for the purposes of Rule 13d-3 under the
Securities Exchange Act of 1934, as amended, the Reporting
Persons may be deemed to be the beneficial owners of, but
hereby disclaim such beneficial ownership of, the foregoing
shares.
Item 5. Ownership of Five Percent or Less of a Class.
Not applicable
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Not applicable
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported By the Parent Holding
Company.
Not applicable
Item 8. Identification and Classification of Members of the Group.
Not applicable
SCHEDULE 13G
CUSIP NO. 89365K206 Page 5 of 6
Item 9. Notice of Dissolution of a Group.
Not applicable
Item 10. Certification.
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and
are not held for the purpose of or with the effect of changing or
influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a
participant in any transaction having that purpose or effect.
SCHEDULE 13G
CUSIP NO. 89365K206 Page 6 of 6
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: November 2, 2005
/s/ Michael A. Roth
--------------------------------
Michael A. Roth
/s/ Brian J. Stark
--------------------------------
Brian J. Stark
SCHEDULE 13G
CUSIP NO. 89365K206
Exhibit 1
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934,
as amended, the undersigned agree to the joint filing on behalf of each of them
of a statement on Schedule 13G (including amendments thereto) with respect to
2,722,772 shares of Common Stock of Transgenomic, Inc. and further agree that
this Joint Filing Agreement shall be included as an exhibit to such joint
filings.
The undersigned further agree that each party hereto is responsible for the
timely filing of such Schedule 13G and any amendments thereto, and for the
completeness and accuracy of the information concerning such party contained
therein; provided, however, that no party is responsible for the completeness or
accuracy of the information concerning any other party making the filing, unless
such party knows or has reason to believe that such information is inaccurate.
IN WITNESS WHEREOF, the parties have executed this Joint Filing Agreement
on November 2, 2005.
/s/ Michael A. Roth
--------------------------------
Michael A. Roth
/s/ Brian J. Stark
--------------------------------
Brian J. Stark